Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study

被引：0
|
作者：
Jean-Luc Raoul
Jean-Luc Van Laethem
Marc Peeters
Catherine Brezault
Fares Husseini
Laurent Cals
Johannes Nippgen
Anja-Helena Loos
Philippe Rougier
机构：
[1] Digestive Oncology Department,Gastroenterology Department
[2] Centre E Marquis,undefined
[3] Hôpital Universitaire Erasme,undefined
[4] Ghent University Hospital,undefined
[5] Hôpital Cochin,undefined
[6] Hôpital Pasteur,undefined
[7] Oncology Service,undefined
[8] Hôpital Font Pré,undefined
[9] BP1412,undefined
[10] Merck KGaA,undefined
[11] Hôpital Ambroise Paré,undefined
来源：
BMC Cancer | / 9卷
关键词：
Epidermal Growth Factor Receptor; Irinotecan; Cetuximab; Folinic Acid; Epidermal Growth Factor Receptor Expression;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer
    Meyerhardt, Jeffrey A.
    Clark, Jeffrey W.
    Supko, Jeffrey G.
    Eder, Joseph P.
    Ogino, Shuji
    Stewart, Clinton F.
    D'Amato, Ferdinando
    Dancey, Janet
    Enzinger, Peter C.
    Zhu, Andrew X.
    Ryan, David P.
    Earle, Craig C.
    Mayer, Robert J.
    Michelini, Ann
    Kinsella, Kate
    Fuchs, Charles S.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (05) : 661 - 670
  • [32] Phase I study of irinotecan by 24-h intravenous infusion in combination with 5-fluorouracil in metastatic colorectal cancer
    Kambe, Mariko
    Kikuchi, Hiroaki
    Gamo, Makio
    Yoshioka, Takashi
    Ohashi, Yasuo
    Kanamaru, Ryunosuke
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2012, 17 (02) : 150 - 154
  • [33] Phase I study of irinotecan by 24-h intravenous infusion in combination with 5-fluorouracil in metastatic colorectal cancer
    Mariko Kambe
    Hiroaki Kikuchi
    Makio Gamo
    Takashi Yoshioka
    Yasuo Ohashi
    Ryunosuke Kanamaru
    International Journal of Clinical Oncology, 2012, 17 : 150 - 154
  • [34] Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer
    Andreas Teufel
    Silke Steinmann
    Jürgen Siebler
    Christiane Zanke
    Herbert Hohl
    Bernd Adami
    M Schroeder
    O Klein
    Thomas Höhler
    Peter R Galle
    Michael Heike
    Markus Moehler
    BMC Cancer, 4
  • [35] Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer
    Shigeta, Kohei
    Hasegawa, Hirotoshi
    Okabayashi, Koji
    Tsuruta, Masashi
    Ishii, Yoshiyuki
    Endo, Takashi
    Ochiai, Hiroki
    Kondo, Takayuki
    Kitagawa, Yuko
    INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (04) : 946 - 954
  • [36] Phase I/II study of irinotecan, 5-fluorouracil, and I-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer
    Goto A.
    Yamada Y.
    Hosokawa A.
    Ura T.
    Arai T.
    Hamaguchi T.
    Muro K.
    Shimada Y.
    Shirao K.
    International Journal of Clinical Oncology, 2004, 9 (5) : 364 - 368
  • [37] Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study
    Seium, Y
    Stupp, R
    Ruhstaller, T
    Gervaz, P
    Mentha, G
    Philippe, M
    Allal, A
    Trembleau, C
    Bauer, J
    Morant, R
    Roth, AD
    ANNALS OF ONCOLOGY, 2005, 16 (05) : 762 - 766
  • [38] Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma
    Folprecht, G
    Lutz, MP
    Schöffski, P
    Seufferlein, T
    Nolting, A
    Pollert, P
    Köhne, CH
    ANNALS OF ONCOLOGY, 2006, 17 (03) : 450 - 456
  • [39] TREATMENT OF ADVANCED COLORECTAL-CANCER WITH FOLINIC ACID AND 5-FLUOROURACIL IN COMBINATION WITH CISPLATINUM
    SAGASTER, P
    ESSL, R
    TEICH, G
    FRITZ, E
    WASILEWSKI, M
    UMEK, H
    DUNSER, E
    MASCHER, H
    MICKSCHE, M
    EUROPEAN JOURNAL OF CANCER, 1994, 30A (09) : 1250 - 1254
  • [40] Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients
    Bécouarn, Y
    Gamelin, E
    Coudert, B
    Négrier, S
    Pierga, JY
    Raoul, JL
    Provençal, J
    Rixe, O
    Krisch, C
    Germa, C
    Bekradda, M
    Mignard, D
    Mousseau, M
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (22) : 4195 - 4201
12345